News | Radiation Therapy | October 17, 2018

IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring

After successful validation of Dolphin interoperability, online patient dose measurements during actual treatment delivery will enable verification of the correctness of each treatment fraction

IBA Dosimetry Enters Interoperability Agreement With Varian for Dolphin Monitoring

October 17, 2018 — IBA (Ion Beam Applications S.A.) announced it has entered into an agreement with Varian with the goal of validating the Dolphin transmission detector for online monitoring of patient treatment.

With the health, security and safety of patients in focus, modern radiation therapy has become highly specialized, which has led to different complex treatment techniques being developed and used daily in patient cancer therapy. This in turn requires new and comprehensive quality assurance (QA) solutions that address the growing number of possible sources and impact of dose deviations, in particular for high-dose cases.

For online patient plan monitoring, IBA Dosimetry is set to release the Dolphin online solution with its Compass 3D verification software, and has therefore entered into an interoperability agreement with Varian.

The Dolphin online functionality enables the measurement of each fraction dose and the verification of the actual radiation dose delivered to patients. The ability to measure treatment accuracy fraction by fraction will provide the confidence and safety needed to deliver the highest quality of care to the patient.

Dolphin includes the following five checks for verification of the complete treatment chain:

  • Real measurement of the plan delivery. In contrast to solutions that purely recalculate the patient plan via log files, the Dolphin advanced high-resolution ionization chamber detector array enables real measurements of each fraction dose and detection of errors in treatment delivery, such as beam line defects, multileaf collimator (MLC) deviations, dose rate changes, flatness/symmetry drifts, gantry positioning errors, etc.;
  • Verification of the real patient plan where no surrogate QA plan is required;
  • Secondary dose calculation with treatment planning system (TPS)-class algorithm. Secondary verification of the TPS dose calculation enables detection of errors in the TPS algorithm, TPS performance or in the TPS export;
  • Machine constancy checks with myQA. In addition, Dolphin’s detector array is optimized to find deviations and trends in linear accelerator (LINAC) constancy for profiles, output and wedge factors; and
  • Independent verification of the treatment planning system. The independent beam model of Dolphin’s verification software enables detection of errors in the TPS configuration and performance, its beam model, commissioning, or the LINAC calibration
     

Dolphin is currently in clinical use around the world for advanced measurement-based pre-treatment patient QA.

For more information: www.iba-dosimetry.com

Related Content

Non-oncology doctors’ knowledge of oncology is frequently not up to date, with risks in the communication with patients  

Getty Images

News | Radiation Oncology | September 20, 2021
September 20, 2021 — The rapid pace of developments in the oncology field, mainly brought by cancer immunotherapy, me
IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...
At the recent 2021 AAPM Meeting in July, Sun Nuclear Corporation featured its comprehensive portfolio of independent, integrated quality management solutions for radiation therapy and diagnostic imaging.
News | Quality Assurance (QA) | September 02, 2021
September 2, 2021 — At the recent 2021 AAPM Meeting
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.